Research progress of IL-33 in gynecological tumors

Interleukin-33(IL-33) was originally described as a high-endothelial intravenous nucleoprotein that was steadily expressed in the nuclei of various cell types in human and mouse tissues, including endothelial cells, epithelial cells and fibroblast-like cells. IL-33 forms IL-33/ST2 signaling pathway by binding to suppression of tumorigenicity2(ST2) and IL-1 receptor accessory protein(IL-1 RAcP), and plays a variety of important roles in immune-mediated diseases such as infection, allergy and autoimmune diseases.In recent years, some studies have shown the potential role of IL-33 in regulating anti-tumor immunity and tumor growth, but its exact function and its potential mechanism in tumor development are still unclear. Ovarian, cervical and endometrial cancers are common gynecologic malignancies. Despite recent advances in surgical resection and systemic chemotherapy of gynecologic tumors, the prognosis of malignant tumors is still poor. In order to further individualize treatment, other prognostic markers and potential therapeutic targets for clinical course prediction are needed. The research on the molecular mechanism of invasive growth and metastasis of malignant tumors may provide new ideas for the treatment of gynecological malignant tumors. This article mainly reviews the biological functions of il-33 and its research progress in gynecological tumors.